Key result
Immediate-intensive statins fail to reduce stroke risk, but cut poor functional outcomes ~29% in non-diabetics.
Why the study?
Does immediate intensive statin therapy reduce stroke and improve functional outcomes compared to delayed therapy in patients with mild ischemic stroke, and does this effect vary by glycemic status?
RCT (n=6,100)
Does immediate intensive statin therapy reduce stroke and improve functional outcomes compared to delayed therapy in patients with mild ischemic stroke, and does this effect vary by glycemic status?
Answers are grounded in this paper and cite their sources.
Immediate intensive statin therapy after mild ischemic stroke improves functional outcomes specifically in patients without type 2 diabetes, but does not appear to offer the same functional benefit to those with diabetes.
AIMS: A subgroup analysis of the Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial to evaluate intensive statin effects in patients with ischemic stroke by glycemic status. METHOD: Patients were stratified into three subgroups based on glycemic status: without type 2 diabetes mellitus (T2DM), with newly diagnosed T2DM, with a history of T2DM. The primary outcomes included stroke and moderate-to-severe bleeding, whereas secondary outcomes comprised composite vascular events, poor functional outcomes, and any bleeding within 90 days. RESULTS: Among 6100 patients, 4038 were without T2DM, 404 had a newly diagnosed T2DM, and 1658 had a history of T2DM. No significant risk reduction of stroke was observed with immediate versus delayed statin therapies across glycemic subgroups (p for interaction = 0.29). Compared to delayed-intensive statin, immediate-intensive statin treatment was associated with reduced risk of poor functional outcome in non-T2DM patients (adjusted relative risk 0.71, 95% CI 0.57-0.90; p = 0.004), but no benefit in those with newly diagnosed T2DM or those with a history of T2DM (p for interaction = 0.003). There was no glycemic status by treatment interaction for risk of bleeding or composite vascular event. CONCLUSIONS: Patients without T2DM derived greater benefit in functional outcomes from immediate-intensive statin after ischemic stroke than those with T2DM.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) conducted an RCT in Mild ischemic stroke (n=6,100). Immediate intensive statin vs. Delayed intensive statin was evaluated on Stroke and moderate-to-severe bleeding (p=0.29). Immediate-intensive statin therapy did not reduce stroke risk across glycemic subgroups, but reduced the risk of poor functional outcome in non-T2DM patients.
Synapse has enriched 10 related papers. Consider them for comparative context: